Blaubeuren, Germany Clinical Trials

A listing of Blaubeuren, Germany clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 229 clinical trials
MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)

Open-label, dose-confirmation and cohort expansion, multicentre, Phase Ib/II study to assess the anti-tumour activity and safety of MEN1611 in combination with cetuximab for the treatment of patients with PIK3CA mutated metastatic colorectal cancer.

metastasis
measurable disease
oxaliplatin
PIK3CA
adenocarcinoma
Ulm
 (9.2 away) Contact site
  • 2 views
  • 27 Jan, 2021
  • +38 other locations
Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

The purpose of this Phase II study is to assess the efficacy and safety of NIS793 with and without spartalizumab in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel in untreated mPDAC.

Novartis Investigative Site
 (9.2 away) Contact site
  • 0 views
  • 12 Jun, 2021
  • +23 other locations
A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer

A phase Ib, open-label platform study of select drug combinations chosen in order to characterize safety and tolerability of each treatment arm tested and to identify recommended doses and regimens for future studies.

Novartis Investigative Site
 (9.2 away) Contact site
  • 0 views
  • 09 May, 2021
  • +16 other locations
Study of Evobrutinib in Participants With RMS (evolutionRMS 1)

The study is to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Teriflunomide (Aubagio), administered orally once daily in participants with Relapsing Multiple Sclerosis (RMS).

aubagio
evobrutinib
teriflunomide
Research Site 269
 (9.3 away) Contact site
  • 0 views
  • 20 Jun, 2021
  • +246 other locations
An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab

The open label study to evaluate effectiveness of treatment with ofatumumab in patients transitioning from commonly used oral MS therapies - fingolimod or dimethyl fumarate, due to breakthrough disease.

ofatumumab
fingolimod
dimethyl fumarate
Novartis Investigative Site
 (9.2 away) Contact site
  • 0 views
  • 12 Jun, 2021
  • +108 other locations
Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation

The purpose of the study is to learn whether the study drug (capmatinib) helps to control lung cancer better compared to a single agent chemotherapy (docetaxel) and whether it is safe when given to patients suffering from a particular type of lung cancer. This type of cancer is called non-small …

measurable disease
growth factor
cancer chemotherapy
lung carcinoma
EGFR
Novartis Investigative Site
 (9.2 away) Contact site
  • 0 views
  • 13 Jun, 2021
  • +42 other locations
Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.

This study will assess the safety, tolerability, and efficacy of Atogepant 60 mg compared with placebo in episodic migraines in participants who previously failed 2 to 4 classes of oral prophylactic treatments.

Neuropoint GmbH
 (9.8 away) Contact site
  • 0 views
  • 12 Jun, 2021
  • +134 other locations
A Study of Subcutaneous Blinatumomab Administration in Acute Lymphoblastic Leukemia (ALL) Patients

The study aims to evaluate the safety and tolerability of subcutaneous (SC) blinatumomab for treatment of Acute Lymphoblastic Leukemia (ALL) and to determine the maximum tolerated dose (MTD), and recommended phase 2 dose (RP2D) of SC administered blinatumomab.

Research site
 (9.2 away) Contact site
  • 0 views
  • 11 Jun, 2021
  • +33 other locations
Multi Centre Trial of DSMM for Newly Diagnosed Multiple Myeloma up to 60 Years

The study is evaluating whether risk-stratification by the means of a chromosomal aberration provides a tool to discriminate between standard and high risk. Risk-adapted therapy is based on allogeneic stem-cell transplantation for high-risk subjects instead of a second autograft in patients with deletion of chromosome 13 who have an HLA-identical …

cell transplantation
autograft
Dept. of Internal Medicine III, University of Ulm
 (9.2 away) Contact site
  • 30 views
  • 07 Nov, 2020
  • +14 other locations
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

This study is evaluating the efficacy of acalabrutinib in combination with bendamustine and rituximab (BR) compared with placebo plus BR in subjects with previously untreated mantle cell lymphoma.

acalabrutinib
cyclin d1
bendamustine
rituximab
Research Site
 (9.2 away) Contact site
  • 1270 views
  • 20 Jun, 2021
  • +245 other locations